Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Tax Provisions (2023 - 2025)

Historic Tax Provisions for Krystal Biotech (KRYS) over the last 3 years, with Q3 2025 value amounting to -$31.4 million.

  • Krystal Biotech's Tax Provisions fell 130769.23% to -$31.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.0 million, marking a year-over-year decrease of 33722.73%. This contributed to the annual value of $6.2 million for FY2024, which is 21536.9% up from last year.
  • Latest data reveals that Krystal Biotech reported Tax Provisions of -$31.4 million as of Q3 2025, which was down 130769.23% from $8.4 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Tax Provisions peaked at $8.4 million during Q2 2025, and registered a low of -$31.4 million during Q3 2025.
  • Moreover, its 3-year median value for Tax Provisions was $2.6 million (2024), whereas its average is -$988428.6.
  • Over the last 5 years, Krystal Biotech's Tax Provisions had its largest YoY gain of 166981.13% in 2025, and its largest YoY loss of 130769.23% in 2025.
  • Quarter analysis of 3 years shows Krystal Biotech's Tax Provisions stood at $2.0 million in 2023, then soared by 57.61% to $3.1 million in 2024, then plummeted by 1113.88% to -$31.4 million in 2025.
  • Its Tax Provisions stands at -$31.4 million for Q3 2025, versus $8.4 million for Q2 2025 and $7.9 million for Q1 2025.